A 70-year-old woman was admitted to the hospital with a subarachnoid hemorrhage. The patient underwent a cerebral aneurysm embolization. On hospital day 14, the patient underwent a lumbar subarachnoid continuous drain insertion because of fever and the enlarged ventricles that were seen on computed tomography (CT) of the head. On hospital day 19, the patient presented with remittent fever (peak at 39.1°C) associated with an altered mental status. An evaluation of the cerebrospinal fluid (CSF) revealed a white blood cell (WBC) count of 53,484/mm 3 (polymorphonucleocytes,75.4%; monocytes, 24.6%), the red blood cells (RBCs) were triple-positive for haptoglobin (ϩϩϩ/HP), the glucose level was 1.26 mg/dl, and the total protein was 14.2 g/dl. The lumbar subarachnoid continuous drain was removed. The patient was started on meropenem 1 g intravenous (i.v.) every 8 h and vancomycin 1 g (i.v.) every 12 h. On hospital day 22, the patient's CSF culture showed Acinetobacter baumannii (polymyxin susceptibility was not tested) that was susceptible only to tigecycline (MIC Յ 1 g/ml) and cefoperazone sulbactam. The same strain of A. baumannii was isolated from the sputum and blood. With permission, the antimicrobial therapy was changed to intravenous tigecycline (100 mg first and then 50 mg every 12 h [q12h]) and cefoperazone sulbactam (3 g q8h). Head CT demonstrated enlarged ventricles compared with that from the previous studies, and an external ventricular drain (EVD) was inserted on hospital day 25. On hospital day 28, the blood culture was negative; however, the same strain of A. baumannii was still isolated from the CSF. With permission, tigecycline 2 mg intraventricular (i.v.t.) every 12 h was started and lasted for 10 days. On hospital day 38, the patient's CSF culture was negative. On hospital day 104, the patient was discharged. A continued 3-month follow-up showed no recurrence. Acinetobacter baumannii accounts for 8.7% to 12.1% of clinical isolates in China (1). In recent years, A. baumannii has become an important cause of nosocomial postneurosurgical meningitis and ventriculitis (2). The mortality rates range from 15% to 71% for Acinetobacter meningitis (3). Colistin (polymyxin E or B) and tigecycline have been demonstrated to be the only antibiotics available for use against these A. baumannii carbapenem-resistant strains (4, 5). As they have a high molecular weight, they cannot pass the blood-brain barrier, and so the guideline suggests combining them with intraventricular colistin in central nervous system (CNS) infection therapy (5). The use of colistin in China was hindered by the unavailability of this drug in the market before 2018. With permission, the extensively drug-resistant A. baumannii CNS infection in our patient was successfully treated using i.v. and i.v.t. tigecycline without adverse effects.
Alcoholic liver disease is one of the diseases with the highest fatality rate worldwide. The cellular process of autophagy which recycles damaged organelles to maintain protein and organelle homeostasis is found to positively influence survival during hepatic insufficiency, although the mechanism is poorly understood. Palmatine (PLT) has a variety of biological functions, such as broad‐spectrum antibacterial action, neuroprotective, antioxidant stress, and antiviral and anti‐inflammatory activities. However, it is not known whether PLT has a protective effect against alcoholic liver injury. Here, we investigated the protective effect of PLT in a cellular model of alcohol‐induced acute liver injury and further explored its mechanism of action. In this study, we show for the first time that PLT attenuates alcohol‐induced hepatocyte injury by promoting autophagy to play an essential protective role. As PLT treatment induced a brief increase in LC3‐II conversion and p62 degradation, it also upregulated the expression of ATG5 and ATG7. The expression levels of the proapoptotic proteins Bax, Caspase 3, and Caspase 9 significantly decreased, while the antiapoptotic protein levels of Bcl‐2 upregulated after treatment with PLT. However, in presence of the autophagy inhibitor, 3‐methyladenine, the effect of PLT in inhibiting ethanol‐induced hepatocyte injury reversed significantly. Mechanistically, the protective effects of PLT may be mediated by promoting the activation of the AMP‐activated protein kinase/mammalian target of rapamycin signaling pathway. Therefore, we believe that the development of alcoholic liver injuries may be controlled by PLT by inhibiting hepatocyte apoptosis through the autophagy pathway. The study lays a solid theoretical and practical basis for future animal models and clinical studies of PLT.
Objective This study was designed to analyze the clinical characteristics, etiological characteristics, drug resistance, and empirical use of antibiotics for community-acquired pyogenic liver abscess (PLA) to provide a basis for rational and effective empirical treatment of PLA in the local area. Methods The clinical data, etiological characteristics, drug resistance, and empirical anti-infective therapy schemes of 606 patients with PLA were collected and analyzed retrospectively. Results The included patients were mainly males, with a male-to-female ratio of 1.3:1. The average age of the patients was 60.3 ± 14.1 years. The underlying diseases were diabetes and biliary tract disease, accounting for 38.7% and 22.3%, respectively. The main clinical manifestations were fever (92.9%), abdominal pain (44.7%), and nausea (33.3%). Imaging findings: the proportion of patients with a single lesion was 74.7%, and 67% of the patients had involvement in the right lobe of the liver. The main pathogen was Klebsiella pneumoniae accounted for 74.9% in blood culture and 84.1% in pus culture, mainly extended-spectrum β-lactamase. In 272 strains negative for extended-spectrum β-lactamase (ESBLs), 100% were resistant to ampicillin and less than 50% were sensitive to nitrofurantoin. Only 36 ESBL-positive strains had higher than 80% sensitivity to carbapenems, β-lactamase inhibitor compound, and amikacin. Patients treated with different treatment methods showed significantly different average length of hospital stay (14 [9–21] vs 13 [8–18]). Empirical anti-infective therapy: Beta-lactamase complex, carbapenems, cephalosporins, and quinolones were used in 280 (37.6%), 180 (29.7%), 180 (29.7%), and 147 (24.3%) patients, respectively. Conclusion Patients with community-acquired PLA in this area are mainly males, and the underlying diseases are mainly diabetes and hepatobiliary system disease. The main clinical manifestation is fever, so patients with fever of unknown cause should pay attention to possible liver abscesses. Based on drug sensitivity tests, the empirical use of antibiotics is somewhat unreasonable.
Background Infective endocarditis (IE) can be caused by a variety of pathogens. Endocarditis due to the Coxiella burnetii ( C. burnetii ) infection is common in patients with negative blood culture results and usually occurs in patients with previous valvular heart disease, impaired immune function, and during pregnancy. The diagnosis is difficult based on the conventional diagnostic method, and serious adverse outcomes may occur in the case of delayed diagnosis. Case Report In the present study, a case of a 43-year-old male patient with previous valvular heart disease was reported. The patient was admitted with a diagnosis of IE, but the etiology was unclear. Accurate diagnosis and treatment were achieved by combining metagenomic next-generation sequencing (mNGS) with Q fever serological antibody assay. Conclusion Metagenomic next-generation sequencing has been increasingly applied in clinical practice in recent years to detect the DNA or RNA in samples, and this could play a decisive role in the etiological diagnosis of some infectious diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.